Evaxion Biotech A/S (EVAX) Competitors $3.09 -0.27 (-8.04%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends EVAX vs. MIRA, BTAI, CYTH, APRE, BFRG, CARM, MEIP, AFMD, PIRS, and FNCHShould you be buying Evaxion Biotech A/S stock or one of its competitors? The main competitors of Evaxion Biotech A/S include MIRA Pharmaceuticals (MIRA), BioXcel Therapeutics (BTAI), Cyclo Therapeutics (CYTH), Aprea Therapeutics (APRE), Bullfrog AI (BFRG), Carisma Therapeutics (CARM), MEI Pharma (MEIP), Affimed (AFMD), Pieris Pharmaceuticals (PIRS), and Finch Therapeutics Group (FNCH). These companies are all part of the "pharmaceutical products" industry. Evaxion Biotech A/S vs. MIRA Pharmaceuticals BioXcel Therapeutics Cyclo Therapeutics Aprea Therapeutics Bullfrog AI Carisma Therapeutics MEI Pharma Affimed Pieris Pharmaceuticals Finch Therapeutics Group MIRA Pharmaceuticals (NASDAQ:MIRA) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings, analyst recommendations and community ranking. Do analysts rate MIRA or EVAX? MIRA Pharmaceuticals currently has a consensus price target of $14.00, suggesting a potential upside of 1,057.02%. Evaxion Biotech A/S has a consensus price target of $55.00, suggesting a potential upside of 1,679.94%. Given Evaxion Biotech A/S's higher probable upside, analysts clearly believe Evaxion Biotech A/S is more favorable than MIRA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Evaxion Biotech A/S 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer MIRA or EVAX? In the previous week, Evaxion Biotech A/S had 12 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 13 mentions for Evaxion Biotech A/S and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.26 beat Evaxion Biotech A/S's score of -0.03 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MIRA Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evaxion Biotech A/S 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Neutral Does the MarketBeat Community prefer MIRA or EVAX? Evaxion Biotech A/S received 20 more outperform votes than MIRA Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave MIRA Pharmaceuticals an outperform vote while only 63.89% of users gave Evaxion Biotech A/S an outperform vote. CompanyUnderperformOutperformMIRA PharmaceuticalsOutperform Votes3100.00% Underperform VotesNo VotesEvaxion Biotech A/SOutperform Votes2363.89% Underperform Votes1336.11% Do insiders & institutionals believe in MIRA or EVAX? 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 11.0% of Evaxion Biotech A/S shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 41.6% of Evaxion Biotech A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, MIRA or EVAX? MIRA Pharmaceuticals has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500. Comparatively, Evaxion Biotech A/S has a beta of -0.23, suggesting that its stock price is 123% less volatile than the S&P 500. Is MIRA or EVAX more profitable? MIRA Pharmaceuticals has a net margin of 0.00% compared to Evaxion Biotech A/S's net margin of -347.83%. Evaxion Biotech A/S's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MIRA PharmaceuticalsN/A -337.44% -280.58% Evaxion Biotech A/S -347.83%N/A -79.40% Which has preferable earnings and valuation, MIRA or EVAX? MIRA Pharmaceuticals has higher earnings, but lower revenue than Evaxion Biotech A/S. Evaxion Biotech A/S is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMIRA PharmaceuticalsN/AN/A-$11.98M-$0.56-2.16Evaxion Biotech A/S$70K259.12-$22.12M-$0.29-10.66 SummaryMIRA Pharmaceuticals beats Evaxion Biotech A/S on 9 of the 17 factors compared between the two stocks. Get Evaxion Biotech A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVAX vs. The Competition Export to ExcelMetricEvaxion Biotech A/SBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.14M$2.96B$5.21B$9.15BDividend YieldN/A1.92%5.13%4.03%P/E Ratio-10.6644.8188.0817.36Price / Sales259.12287.611,243.2778.03Price / CashN/A192.9043.7535.97Price / Book-2.643.965.314.79Net Income-$22.12M-$41.02M$122.62M$225.00M7 Day Performance263.53%0.19%0.61%2.62%1 Month Performance-32.83%-1.72%2.56%3.81%1 Year Performance-90.78%-2.23%25.79%20.10% Evaxion Biotech A/S Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVAXEvaxion Biotech A/S2.4826 of 5 stars$3.09-8.0%$55.00+1,679.9%-90.8%$18.14M$70,000.00-10.6660Analyst RevisionMIRAMIRA Pharmaceuticals2.8628 of 5 stars$1.19-5.6%$14.00+1,076.5%+45.7%$19.71MN/A-2.122Positive NewsBTAIBioXcel Therapeutics4.6238 of 5 stars$0.38+1.7%$2.81+632.8%-86.6%$19.05M$2.28M-0.1890CYTHCyclo Therapeutics1.7732 of 5 stars$0.66+6.0%$0.95+43.9%-51.5%$18.99M$870,725.00-0.739Positive NewsAPREAprea Therapeutics3.8201 of 5 stars$3.42-6.6%$15.50+353.2%-28.6%$18.59M$580,000.00-1.227Positive NewsGap DownBFRGBullfrog AI0.3717 of 5 stars$2.11-0.5%N/A-56.6%$18.38M$60,000.00-2.484Positive NewsCARMCarisma Therapeutics3.962 of 5 stars$0.44-7.0%$4.94+1,027.9%-80.8%$18.29M$14.92M-0.2820Short Interest ↓MEIPMEI Pharma4.4408 of 5 stars$2.72+0.7%$7.00+157.4%-39.3%$18.12M$65.30M-0.39100Analyst ForecastNews CoveragePositive NewsGap DownAFMDAffimed4.2971 of 5 stars$1.12-5.1%$13.50+1,105.4%-80.5%$18.03M$877,000.000.00200Short Interest ↓Positive NewsPIRSPieris Pharmaceuticals1.2422 of 5 stars$13.60-15.7%N/A+2.0%$17.95M$42.81M-1.12140Analyst ForecastGap DownFNCHFinch Therapeutics GroupN/A$10.90-0.5%N/A+284.0%$17.51M$110,000.00-1.24190 Related Companies and Tools Related Companies MIRA Pharmaceuticals Competitors BioXcel Therapeutics Competitors Cyclo Therapeutics Competitors Aprea Therapeutics Competitors Bullfrog AI Competitors Carisma Therapeutics Competitors MEI Pharma Competitors Affimed Competitors Pieris Pharmaceuticals Competitors Finch Therapeutics Group Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EVAX) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion Biotech A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Evaxion Biotech A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
